211 related articles for article (PubMed ID: 25193961)
1. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
2. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
3. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
Pulikkan JA; Peramangalam PS; Dengler V; Ho PA; Preudhomme C; Meshinchi S; Christopeit M; Nibourel O; Müller-Tidow C; Bohlander SK; Tenen DG; Behre G
Blood; 2010 Dec; 116(25):5638-49. PubMed ID: 20889924
[TBL] [Abstract][Full Text] [Related]
4. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
Quintana-Bustamante O; Lan-Lan Smith S; Griessinger E; Reyal Y; Vargaftig J; Lister TA; Fitzgibbon J; Bonnet D
Leukemia; 2012 Jul; 26(7):1537-46. PubMed ID: 22371011
[TBL] [Abstract][Full Text] [Related]
7. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
9. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
[TBL] [Abstract][Full Text] [Related]
10. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
11. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
12. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.
Pulikkan JA; Dengler V; Peer Zada AA; Kawasaki A; Geletu M; Pasalic Z; Bohlander SK; Ryo A; Tenen DG; Behre G
Leukemia; 2010 May; 24(5):914-23. PubMed ID: 20376080
[TBL] [Abstract][Full Text] [Related]
13. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
Fasan A; Alpermann T; Haferlach C; Grossmann V; Roller A; Kohlmann A; Eder C; Kern W; Haferlach T; Schnittger S
PLoS One; 2013; 8(2):e54365. PubMed ID: 23383300
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
16. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.
Haefliger S; Klebig C; Schaubitzer K; Schardt J; Timchenko N; Mueller BU; Pabst T
Blood; 2011 Jun; 117(22):5931-40. PubMed ID: 21471526
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation.
Wurm AA; Zjablovskaja P; Kardosova M; Gerloff D; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Benoukraf T; Fricke S; Hilger N; Müller AM; Bill M; Schwind S; Tenen DG; Niederwieser D; Alberich-Jorda M; Behre G
Nat Commun; 2017 Jun; 8(1):46. PubMed ID: 28663557
[TBL] [Abstract][Full Text] [Related]
18. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
